Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
Subst Abuse Treat Prev Policy ; 8: 1, 2013 Jan 10.
Article in English | MEDLINE | ID: mdl-23302491

ABSTRACT

BACKGROUND: Insecure early attachment experiences have been reported to play an important role in the manifestation in alcoholism. The purpose of this study was to investigate the relationship of attachment styles with anxiety, anxiety coping and dysfunctional personality styles, as well as with the prevalence of personality disorders, and adverse life-events in adolescence. METHODS: 59 inpatient alcohol addicted male (n=43) and female (n=16) patients were characterized by an attachment style scale (Relationships-style-questionnaire-RSQ) and completed a questionnaire battery comprising the State-Trait-Anxiety-Inventory (STAI), the Anxiety-Coping-Inventory (ABI), Temperament-and-character-inventory (TCI), Personality-system-interaction-inventory (PSI), and gave information on sociodemography, alcohol history, and adolescent adverse events. A structured interview (SKID-II) was performed to diagnose personality disorders. RESULTS: Only 33% of subjects had a secure attachment style. Insecure attachment was associated with significantly higher trait-anxiety, higher cognitive avoidance to control anxiety, and higher values on most personality style dimensions directed to the pathological pole. CONCLUSIONS: Despite the limitation due to a small sample size, the results of this study show that the consideration of attachment styles is of significance in the diagnosis and therapy of alcohol addiction. Attachment may characterize different styles to control emotional aspects, anxiety cues and interpersonal relationships in individuals suffering from alcohol addiction.


Subject(s)
Adaptation, Psychological , Alcoholism/psychology , Anxiety Disorders/epidemiology , Anxiety/complications , Object Attachment , Personality , Adult , Aged , Alcoholism/diagnosis , Anxiety/epidemiology , Anxiety Disorders/complications , Female , Humans , Male , Middle Aged , Personality Disorders/complications , Personality Disorders/epidemiology , Prevalence , Surveys and Questionnaires
2.
Neuropsychobiology ; 56(2-3): 119-22, 2007.
Article in English | MEDLINE | ID: mdl-18182828

ABSTRACT

INTRODUCTION: The aim of this naturalistic study was to gain more information about the elevation of basal hypothalamic-pituitary-adrenal (HPA) activity in relationship to symptom severity in specific subtypes of depressive episodes. METHOD: Hamilton Depression Rating Scale scores and aggregated nocturnal urinary cortisol excretion were measured in 4 groups of inpatients with depressive episodes (n = 48; monopolar nonpsychotic, monopolar psychotic, bipolar nonpsychotic and bipolar psychotic) at the beginning and at the end of inpatient treatment. RESULTS: The initial elevation of nocturnal urinary cortisol excretion was most pronounced in psychotic patients. At the end of treatment, the Hamilton Depression Rating Scale scores had decreased significantly in all patients to comparable levels, whereas the nocturnal cortisol excretion values were still relatively elevated in mono- and bipolar psychotic patients compared to mono- and bipolar nonpsychotic ones. CONCLUSION: The observation that the basal HPA activity remains elevated even after remission of symptoms in patients with psychotic depression supports the concept that a dysfunctional regulation of the HPA system is possibly a trait- rather than a state-related feature.


Subject(s)
Depression/complications , Depression/urine , Hydrocortisone/urine , Psychotic Disorders/complications , Psychotic Disorders/urine , Adult , Female , Humans , Male , Middle Aged , Severity of Illness Index
3.
J Neurosci Res ; 84(7): 1575-9, 2006 Nov 15.
Article in English | MEDLINE | ID: mdl-16998917

ABSTRACT

Neuronal injury is frequent in bacterial meningitis, resulting in a high rate of death and neurological sequelae. In a search of potential neuroprotective strategies for treatment of bacterial meningitis, the antioxidant melatonin was neuroprotective in cell culture experiments and in a rabbit Streptococcus pneumoniae meningitis model, when treatment was started at the time of infection. In the present study, adjunctive melatonin treatment applied from the beginning of antibiotic therapy 12 hr after infection at a dose of 1.67 mg/kg/hr resulted in plasma concentrations of 451 +/- 198 ng/ml, cerebrospinal fluid (CSF) concentrations of 154 +/- 57 ng/ml and a CSF-to-plasma ratio of 0.38 +/- 0.19 (mean +/- SD). Melatonin therapy had antiinflammatory effects but did not reduce neuronal injury in either a rabbit model of gram-positive Streptococcus pneumoniae or gram-negative Escherichia coli meningitis.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Melatonin/therapeutic use , Meningitis, Bacterial/drug therapy , Streptococcus pneumoniae , Animals , Antioxidants/therapeutic use , Apoptosis/drug effects , Cell Count/methods , Dinoprostone/cerebrospinal fluid , Disease Models, Animal , Hippocampus/microbiology , Hippocampus/pathology , Meningitis, Bacterial/cerebrospinal fluid , Meningitis, Bacterial/complications , Neurons/drug effects , Rabbits , Statistics, Nonparametric , Time Factors
4.
Psychopharmacology (Berl) ; 185(1): 11-8, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16432682

ABSTRACT

RATIONALE: Increased activity of the hypothalamic-pituitary-adrenal (HPA) axis is an important aspect of the pathophysiology of major depression and schizophrenia. Despite the usefulness of atypical antipsychotics in the treatment of depression and their positive influence on cognitive functioning possibly related to their impact on cortisol, little is known about their effect on HPA axis function. OBJECTIVE: Therefore, this double-blind, placebo-controlled, randomized cross-over study investigated the influence of the atypical antipsychotics quetiapine and olanzapine in comparison with haloperidol and placebo on plasma adrenocorticotropic hormone (ACTH), cortisol, and prolactin levels. Eleven healthy male volunteers were studied during four sessions one week apart, orally receiving placebo, quetiapine (50 mg), olanzapine (5 mg), or haloperidol (3 mg). Blood samples were taken at hourly intervals from 0900 until 1700 hours. For ACTH, cortisol, and prolactin a significant effect of treatment condition (p < or = 0.005; p < or = 0.035; p < or = 0.0001, respectively) for area under the curve (AUC) was found. In comparison to placebo, quetiapine and olanzapine significantly reduced ACTH (p < or = 0.002; p < or = 0.05, respectively) and cortisol (p < or = 0.005; p < or = 0.03, respectively). No effect of haloperidol on AUC of ACTH or cortisol levels was observed. In comparison with placebo, haloperidol (p < or = 0.0001) and olanzapine (p < or = 0.0001) elevated AUC of prolactin plasma levels, whereas no significant effect was observed for quetiapine as a main effect of treatment condition. The atypical antipsychotics' strong influence on HPA-function with pronounced ACTH and cortisol lowering is possibly related to the atypicals' blockade of serotonergic receptors, but blockade of adrenergic or histaminergic receptors may play a role as well. The observed HPA-axis down-regulation may be clinically important for the atypicals' effects on depressive symptomatology and cognitive functioning.


Subject(s)
Antipsychotic Agents/pharmacology , Dibenzothiazepines/pharmacology , Haloperidol/pharmacology , Hypothalamo-Hypophyseal System/drug effects , Pituitary-Adrenal System/drug effects , Adrenocorticotropic Hormone/blood , Adult , Benzodiazepines/pharmacology , Cross-Over Studies , Double-Blind Method , Humans , Hydrocortisone/blood , Male , Olanzapine , Prolactin/blood , Quetiapine Fumarate
5.
Br J Clin Pharmacol ; 60(3): 330-6, 2005 Sep.
Article in English | MEDLINE | ID: mdl-16120074

ABSTRACT

AIMS: To determine the influence of the atypical antipsychotic ziprasidone on cortisol excretion. METHODS: In a double-blind, placebo-controlled, randomized cross-over design 11 healthy male subjects were studied twice for 2 consecutive nights (N1, undisturbed sleep conditions; N2, exposure to acoustic stress) 5 days apart. Placebo or ziprasidone 40 mg was administered orally 2 h before bedtime on N1 and N2. Urine was collected during three fractionated collection periods (evening; night; morning) for the later determination of cortisol concentrations by standard radioimmunoassays. RESULTS: Ziprasidone decreased the total amount of cortisol excreted by 4.9 (95% CI 3.3, 6.5) microg during N1 and by 10.8 (95% CI 5.7, 15.8) microg during N2 (P < 0.002). This effect was still detectable in the morning (P < 0.02), with decreases of 5.8 (95% CI -2.8, 14.4) microg after N1 and by 12.1 (95% CI 2.8, 21.4) microg after N2. The effect subsided in the evening. A significant intervention-condition interaction (P < 0.02), was found. The significant increase in cortisol excretion during acoustic stress observed with placebo was absent after treatment with ziprasidone. CONCLUSIONS: The significant decrease in nocturnal cortisol excretion following ziprasidone reflects a decreased activity of the HPA-axis in healthy subjects. This effect may be an important contributor to the mode of action of ziprasidone in different patient populations, particularly in the treatment of depression and in cognitive impairment in schizophrenia.


Subject(s)
Antipsychotic Agents/pharmacology , Hydrocortisone/urine , Piperazines/pharmacology , Thiazoles/pharmacology , Acoustic Stimulation/adverse effects , Adult , Double-Blind Method , Humans , Male , Stress, Physiological/urine
6.
J Infect Dis ; 191(5): 783-90, 2005 Mar 01.
Article in English | MEDLINE | ID: mdl-15688296

ABSTRACT

Neuronal injury in bacterial meningitis is a consequence of the direct toxicity of bacterial components and inflammatory and oxidative mechanisms. Adjunctive therapy with melatonin was investigated in vitro and in experimental meningitis. Cellular damage was reduced by treatment with melatonin in organotypic hippocampal cultures (P<.001) and in human SH-SY5Y cells (P<.01). Rabbits were infected intracisternally with Streptococcus pneumoniae and received either melatonin (20 mg/kg body weight/24 h; n=12) or saline (n = 11) intravenously. Twelve hours later, all rabbits received ceftriaxone (10 mg/kg body weight/h). The density of apoptotic dentate granule cells was lower in melatonin-treated rabbits (81.8+/-52.9 vs. 227.5+/-127.9 cells/mm(2); P=.002). The activity of superoxide dismutase in the hippocampal formation was higher (P=.04), and nitrite concentrations in cerebrospinal fluid were lower, after treatment with melatonin (P=.003). Melatonin reduced neuronal injury in vitro and in experimental meningitis, and it may be suitable as adjunctive therapy in human meningitis.


Subject(s)
Antioxidants/pharmacology , Melatonin/pharmacology , Meningitis, Pneumococcal/drug therapy , Animals , Antioxidants/metabolism , Cell Death/drug effects , Cell Line , Cells, Cultured , Hippocampus/cytology , Humans , Melatonin/cerebrospinal fluid , Meningitis, Pneumococcal/cerebrospinal fluid , Meningitis, Pneumococcal/pathology , Mice , Mice, Inbred C57BL , Neurons/drug effects , Oxidative Stress , Rabbits , Superoxide Dismutase/physiology
7.
Pharmacopsychiatry ; 37(4): 163-7, 2004 Jul.
Article in English | MEDLINE | ID: mdl-15467972

ABSTRACT

BACKGROUND: The benzamide tiapride, a selective dopamine D2/D3-receptor antagonist, can be used effectively in children to treat tic disorders and stuttering. Tiapride is a clinically safe substance (even during long-term treatment and when given to young children). Unfortunately, its probable effects on general brain development and the maturation of the dopaminergic system have not been investigated. Thus, important information for drug treatment in children is missing. Therefore, this study in rats describes tiapride's effects on several parameters of dopaminergic activity (dopamine transporter, D2 receptor, dopamine, DOPAC, and homovanillic acid in the striatum) seen after tiapride administration (30 mg/kg/day) to prepubertal (from day 25-39) and postpubertal (from day 50-64) rats. METHODS: Three groups of rats (n = 6) received tiapride within their drinking water for 14 days. Two groups were treated before puberty; one of those was killed at day 50, the other at day 90. The group treated after puberty was measured at day 90. A fourth group (n = 6) was treated from day 50 to day 53 and measured under tiapride at day 53. Changes were measured by ligand-binding assays (KD and Bmax values of dopamine transporter by [3H]-GBR binding and D2 receptor by [3H]- spiperone binding) and by HPLC (concentrations of dopamine, DOPAC, and homovanillic acid). RESULTS: The density of dopamine transporters and D2 receptors remained unaffected after early (day 25) and late (day 50) tiapride administration. Only during the treatment period could a significant reduction of D2-receptor binding (displacement of spiperone) and of dopamine and DOPAC levels be stated. CONCLUSIONS: These data suggest that tiapride treatment during postnatal brain development causes no long-lasting changes in the development of the central dopaminergic system and is in line with clinical experience in children.


Subject(s)
Dopamine Antagonists/pharmacology , Dopamine/metabolism , Membrane Glycoproteins/drug effects , Membrane Transport Proteins/drug effects , Nerve Tissue Proteins/drug effects , Receptors, Dopamine D2/drug effects , Tiapamil Hydrochloride/pharmacology , 3,4-Dihydroxyphenylacetic Acid/metabolism , Age Factors , Animals , Binding Sites , Chromatography, High Pressure Liquid/methods , Corpus Striatum/drug effects , Corpus Striatum/metabolism , Dopamine Antagonists/pharmacokinetics , Dopamine Plasma Membrane Transport Proteins , Homovanillic Acid/metabolism , Rats , Spiperone/pharmacokinetics , Tiapamil Hydrochloride/administration & dosage , Time Factors
8.
Psychopharmacology (Berl) ; 174(3): 414-20, 2004 Jul.
Article in English | MEDLINE | ID: mdl-14735295

ABSTRACT

RATIONALE: Hypothalamic-pituitary-adrenal (HPA) axis dysfunction is a frequent finding in psychiatric disorders, including psychotic depression and schizophrenia. Conflicting results exist concerning the influence of antipsychotics on the HPA-axis. OBJECTIVE: Therefore, this double-blind, placebo-controlled, randomized cross-over study investigated the effect of quetiapine on nocturnal urinary cortisol and melatonin excretion in 13 healthy male subjects under conditions of undisturbed and experimentally disturbed sleep. METHODS: Volunteers were studied 3 times for 3 consecutive nights (N0, adaptation; N1, standard sleep conditions; N2, acoustic stress) 4 days apart. Placebo, quetiapine 25 mg or quetiapine 100 mg was administered orally 1 h before bedtime on nights 1 and 2. Urine produced during the 8-h bedtime period was collected for later determination of cortisol and melatonin concentrations by standard radioimmunoassays. RESULTS: MANOVA showed a significant effect for N1 vs. N2 with elevated total amount of cortisol ( p<0.005) and melatonin ( p<0.05) excretion after acoustic stress. Both quetiapine 25 mg and 100 mg significantly ( p<0.0005) reduced the total amount of cortisol excretion in comparison to placebo. No interaction effect of stress condition was observed. There was no effect of quetiapine on melatonin levels. CONCLUSION: The significant reduction of nocturnal cortisol excretion following quetiapine reflects a decreased activity of the HPA-axis in healthy subjects. This finding may be an important aspect in quetiapine's mode of action in different patient populations.


Subject(s)
Antipsychotic Agents/pharmacology , Circadian Rhythm/drug effects , Dibenzothiazepines/pharmacology , Hydrocortisone/urine , Acoustic Stimulation/adverse effects , Adult , Cross-Over Studies , Dose-Response Relationship, Drug , Dose-Response Relationship, Radiation , Double-Blind Method , Humans , Male , Melatonin/urine , Multivariate Analysis , Quetiapine Fumarate , Radioimmunoassay/methods , Stress, Physiological/drug therapy , Stress, Physiological/etiology , Stress, Physiological/urine
9.
Article in English | MEDLINE | ID: mdl-12787858

ABSTRACT

It was investigated whether subchronic application of 30 mg/kg ketamine (Ket) induces reliable changes in behaviour and parameters of dopaminergic, glutamatergic, and serotonergic neurotransmissions, which might be the basis of an animal model in schizophrenia research. To test this, rats were injected with 30 mg/kg ip Ket daily for five consecutive days. In response to the first Ket injection, there was a decrease in activity time representing an acute Ket effect. Following the fifth injection, there were no differences between Ket- and saline (sal)-injected control rats in activity time, which might be a tolerance reaction. The following experiments were performed 2 or 4 weeks after Ket treatment. There were no effects on anxiety in either vehicle or Ket-treated rats using either low or high illumination levels in the elevated plus-maze. In the social interaction test, both groups of rats spent comparable times in social contact. The percentage of nonaggressive behaviour was decreased in Ket-treated rats. Two weeks after completion of the treatment, there was no effect on prepulse inhibition (PPI). Four weeks after the final Ket injection, latent inhibition (LI) was disrupted. There was no difference in the animals' activity in reaction to apomorphine (Apo) administration. Ket-treated rats injected with 0.1 mg/kg MK-801 showed an enhancement in locomotor activity. Ket treatment leads to an increase in D2 receptor binding in the hippocampus and a decrease in glutamate receptor binding in the frontal cortex. The authors did not find any changes in D1 receptor binding. The density of dopamine transporters was increased in the striatum. The density of 5-HT transporters was increased in the striatum, the hippocampus, and the frontal cortex. The results suggest that subchronic treatment with subanaesthetic doses of Ket induce schizophrenia-related alterations, which might be a useful animal model in the study of this disease.


Subject(s)
Anesthetics, Dissociative/pharmacology , Ketamine/pharmacology , Schizophrenia/physiopathology , Anesthetics, Dissociative/administration & dosage , Anesthetics, Dissociative/adverse effects , Animals , Anxiety , Disease Models, Animal , Injections, Intraperitoneal , Ketamine/administration & dosage , Ketamine/adverse effects , Locomotion , Male , Rats , Rats, Sprague-Dawley , Receptors, Dopamine/drug effects , Receptors, Dopamine/physiology , Receptors, Neurotransmitter/drug effects , Receptors, Neurotransmitter/physiology , Receptors, Serotonin/drug effects , Receptors, Serotonin/physiology , Synaptic Transmission
10.
Neurosci Lett ; 324(2): 159-63, 2002 May 17.
Article in English | MEDLINE | ID: mdl-11988351

ABSTRACT

Recent research provides evidence for an interaction between sleep and the activation of the hypothalamic-pituitary-adrenal (HPA)-axis, but detailed studies in patients are still missing. We investigated hourly evening and nocturnal plasma cortisol secretion and sleep in seven male patients with severe chronic primary insomnia and age- and gender-matched controls. Evening and nocturnal cortisol levels were significantly increased in patients. Evening cortisol correlated with the number of nocturnal awakenings in patients and controls. Additionally, patients showed significant correlations between sleep parameters and the first 4 h of nocturnal cortisol secretion. These results are indicative of changes in the HPA system in insomnia and may reflect a pathophysiological mechanism of chronic insomnia resulting in a vicious cycle of both disturbed HPA functions and chronic insomnia according to the arousal hypothesis of insomnia.


Subject(s)
Circadian Rhythm/physiology , Hydrocortisone/metabolism , Hypothalamo-Hypophyseal System/metabolism , Pituitary-Adrenal System/metabolism , Sleep Disorders, Circadian Rhythm/blood , Sleep Initiation and Maintenance Disorders/blood , Sleep/physiology , Adult , Arousal/physiology , Chronic Disease , Humans , Hydrocortisone/blood , Hypothalamo-Hypophyseal System/physiopathology , Male , Middle Aged , Pituitary-Adrenal System/physiopathology , Sleep Disorders, Circadian Rhythm/physiopathology , Sleep Initiation and Maintenance Disorders/physiopathology , Stress, Physiological/blood , Stress, Physiological/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL
...